Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 33.62M | 33.56M | 33.36M | 36.16M | 29.98M | 23.09M |
Gross Profit | 19.65M | 19.08M | 18.46M | 21.77M | 19.85M | 14.13M |
EBITDA | -3.36M | -2.84M | -3.38M | 1.13M | 1.73M | -165.00K |
Net Income | -9.15M | -10.09M | -10.83M | -5.55M | -2.71M | -4.41M |
Balance Sheet | ||||||
Total Assets | 34.26M | 36.16M | 42.02M | 52.27M | 46.59M | 46.78M |
Cash, Cash Equivalents and Short-Term Investments | 6.51M | 7.26M | 6.78M | 5.43M | 12.59M | 10.60M |
Total Debt | 1.17M | 16.44M | 15.63M | 8.44M | 8.03M | 10.88M |
Total Liabilities | 31.59M | 31.18M | 29.33M | 30.44M | 21.18M | 20.89M |
Stockholders Equity | 2.67M | 4.97M | 12.69M | 21.83M | 25.41M | 25.89M |
Cash Flow | ||||||
Free Cash Flow | -668.00K | -1.45M | -5.54M | -4.66M | -2.15M | -63.00K |
Operating Cash Flow | 442.00K | 188.00K | -519.00K | -1.11M | 1.51M | 2.10M |
Investing Cash Flow | -1.11M | -1.64M | -5.02M | -4.18M | -7.13M | -2.16M |
Financing Cash Flow | 18.00K | 1.93M | 6.86M | -500.00K | 92.00K | 2.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $76.63M | 42.40 | 3.46% | ― | 24.75% | -61.29% | |
54 Neutral | $26.09M | ― | -450.47% | ― | 9.47% | 81.37% | |
54 Neutral | $26.09M | ― | -450.47% | ― | 9.47% | 81.37% | |
49 Neutral | $9.72M | ― | -151.23% | ― | 3.30% | 31.84% | |
49 Neutral | $8.32M | ― | -72.70% | ― | 5.05% | 26.13% | |
47 Neutral | $10.33M | 0.85 | -499.57% | ― | -33.92% | ― | |
46 Neutral | C$194.71M | -4.33 | -8.58% | 2.64% | 13.66% | -0.73% | |
42 Neutral | $9.34M | ― | -56.80% | ― | -91.22% | 11.84% |
On May 19, 2025, STRATA Skin Sciences announced a significant expansion of CPT codes for reimbursement of 308nm excimer laser treatments, which now include multiple inflammatory and autoimmune skin conditions beyond psoriasis. This change, reflecting over 20 years of clinical evidence, is expected to broaden market access from 10 million to over 30 million potential patients, reducing reimbursement barriers and supporting STRATA’s mission to provide non-drug dermatologic solutions. The update is anticipated to drive commercial growth and expand the use of STRATA’s XTRAC platform, benefiting patients, providers, and insurers.
The most recent analyst rating on (SSKN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
On May 14, 2025, STRATA Skin Sciences announced its financial results for the first quarter ending March 31, 2025. The company reported a revenue increase of 1% to $6.8 million, with international growth offsetting domestic declines. Gross margins improved significantly by 790 basis points, and operating expenses decreased by 5%. Despite a net loss of $2.4 million, the company showed progress with improved adjusted EBITDA and a strategic focus on international markets, which now account for 36% of total revenue.
The most recent analyst rating on (SSKN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.